

## Standing Committee for Reviewing Emerging Medical Technologies

### Purpose:

This standing committee serves to ensure consistency across all emerging medical technology licensing guidance documents, provide more flexibility, and help to prioritize the reviews by considering available resources, and consider the timeline of the NRC review relative to the reviews by the U.S. Food and Drug Administration (FDA) and/or the Agreement States.

### Participants:

The charter institutes the following staff to serve on the standing committee: an NRC Co-Chair (Katie Tapp), NRC Coordinator (Dan Shaw), Agreement State Co-Chair (Meghan Cromie, CO), Office of General Counsel (OGC) Representative (Katerina Georgiev), Alternate NRC Regional Representative (Magdalena Gryglak, Region IV), Alternate OGC Representative (Jen Scro), and Alternate Agreement State Representative (John "Jay" Pavlica, TX).

### Activities:

Committee meetings are held monthly, or as needed.



### Newly Issued:

Technology Name	Status	Document Date	Documents
LV Liberty Vision Yttrium-90 Disc & iWand® Ophthalmic System	Licensed under 35.1000	6/2025	Licensing Guidance & Consolidated Technical Analysis
RefleXion Medical Radiotherapy System	Licensed under 35.200	4/2025	MEMO: Licensing for RefleXion Medical Radiotherapy System
Thorium Generators	Licensed as byproduct material	4/2025	MEMO: Licensing of Thorium Generators
Alpha Tau Alpha DaRT™ Manual Brachytherapy	Licensed under 35.1000	2/2025	Licensing Guidance
Eye90 microspheres	Licensed under 35.1000	9/2024	Licensing Guidance
Akesis Galaxy RTi	Licensed under 35.1000	8/2024	Licensing Guidance
Technegas® Aerosol & Technegas Plus System	Licensed under 35.200	1/2024	MEMO: Licensing for Technegas Aerosol & Technegas Plus System